Published Date: 25 Sep 2025
Molecular profiling has transformed cancer care, but 30% of high-risk pediatric cancers do not have actionable therapeutic targets, limiting personalized treatment options and negatively affecting survival outcomes.
Read Full NewsTrial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.
The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.
COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension
Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial
FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates
1.
Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'
2.
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer
3.
Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer
4.
When does a melanoma metastasize? Implications for management
5.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
1.
Leptomeningeal Carcinomatosis: Symptoms, Causes, and Treatment Options
2.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
3.
Molecular & Genetic Oncology: Emerging Frontiers in 2025
4.
The Essential Roadmap for Nutritional Excellence in Head and Neck Cancer Care
5.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation